Dilon to distribute SurgicEye imaging technologies in the U.S.
Dilon Diagnostics, a developer of molecular breast imaging technologies, has become the exclusive U.S. distributor of products from SurgicEye, developer of intraoperative soft tissue imaging and navigation technologies.
The Munich-based SurgicEye said its declipseSPECT / CSS300 provides intraoperative 3D image visualization and navigation for gamma probes during radio-guided surgery. The technology extends commonly used gamma probes and combines imaging and image viewing as a tool to resect radioactively labeled structures like primary breast tumors, metastases and sentinel lymph nodes in a minimally invasive approach. This intraoperative imaging technology contributes to quality assurance and provides evidence for sentinel lymph node and tumor resection during the surgery.
SurgicEye received FDA clearance of its declipseSPECT / CSS300 intraoperative gamma probe 3D visualization device.
The Munich-based SurgicEye said its declipseSPECT / CSS300 provides intraoperative 3D image visualization and navigation for gamma probes during radio-guided surgery. The technology extends commonly used gamma probes and combines imaging and image viewing as a tool to resect radioactively labeled structures like primary breast tumors, metastases and sentinel lymph nodes in a minimally invasive approach. This intraoperative imaging technology contributes to quality assurance and provides evidence for sentinel lymph node and tumor resection during the surgery.
SurgicEye received FDA clearance of its declipseSPECT / CSS300 intraoperative gamma probe 3D visualization device.